Literature DB >> 29150461

GABA Type A Receptor Activation in the Allosteric Coagonist Model Framework: Relationship between EC50 and Basal Activity.

Gustav Akk1, Daniel J Shin2, Allison L Germann2, Joe Henry Steinbach2.   

Abstract

The concerted transition model for multimeric proteins is a simple formulation for analyzing the behavior of transmitter-gated ion channels. We used the model to examine the relationship between the EC50 for activation of the GABA type A (GABAA) receptor by the transmitter GABA and basal activity employing concatemeric ternary GABAA receptors expressed in Xenopus oocytes. Basal activity, reflecting the receptor function in the absence of the transmitter, can be changed either by mutation to increase constitutive activity or by the addition of a second agonist (acting at a different site) to increase background activity. The model predicts that either mechanism for producing a change in basal activity will result in identical effects on the EC50 We examined receptor activation by GABA while changing the level of basal activity with the allosterically acting anesthetics propofol, pentobarbital, or alfaxalone. We found that the relationship between EC50 and basal activity was well described by the concerted transition model. Changes in the basal activity by gain-of-function mutations also resulted in predictable changes in the EC50 Finally, we altered the number of GABA-binding sites by a mutation and again found that the relationship could be well described by the model. Overall, the results support the idea that interactions between the transmitter GABA and the allosteric agonists propofol, pentobarbital, or alfaxalone can be understood as reflecting additive and independent free energy changes, without assuming any specific interactions.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29150461      PMCID: PMC5749490          DOI: 10.1124/mol.117.110569

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  42 in total

1.  Occupation of either site for the neurosteroid allopregnanolone potentiates the opening of the GABAA receptor induced from either transmitter binding site.

Authors:  John Bracamontes; Megan McCollum; Caroline Esch; Ping Li; Jason Ann; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2011-04-15       Impact factor: 4.436

2.  GABAA receptor subunit gamma2 and delta subtypes confer unique kinetic properties on recombinant GABAA receptor currents in mouse fibroblasts.

Authors:  K F Haas; R L Macdonald
Journal:  J Physiol       Date:  1999-01-01       Impact factor: 5.182

Review 3.  Allosteric receptors after 30 years.

Authors:  J P Changeux; S J Edelstein
Journal:  Neuron       Date:  1998-11       Impact factor: 17.173

4.  Perfection of a synaptic receptor: kinetics and energetics of the acetylcholine receptor.

Authors:  M B Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

Review 5.  Monod-Wyman-Changeux allosteric mechanisms of action and the pharmacology of etomidate.

Authors:  Stuart A Forman
Journal:  Curr Opin Anaesthesiol       Date:  2012-08       Impact factor: 2.706

6.  Modes and models of GABA(A) receptor gating.

Authors:  Gareth M C Lema; Anthony Auerbach
Journal:  J Physiol       Date:  2006-02-02       Impact factor: 5.182

7.  Gating allosterism at a single class of etomidate sites on alpha1beta2gamma2L GABA A receptors accounts for both direct activation and agonist modulation.

Authors:  Dirk Rüsch; Huijun Zhong; Stuart A Forman
Journal:  J Biol Chem       Date:  2004-03-11       Impact factor: 5.157

8.  Single-channel behavior of heteromeric alpha1beta glycine receptors: an attempt to detect a conformational change before the channel opens.

Authors:  Valeria Burzomato; Marco Beato; Paul J Groot-Kormelink; David Colquhoun; Lucia G Sivilotti
Journal:  J Neurosci       Date:  2004-12-01       Impact factor: 6.167

9.  A nonequilibrium binary elements-based kinetic model for benzodiazepine regulation of GABAA receptors.

Authors:  Marcel P Goldschen-Ohm; Alexander Haroldson; Mathew V Jones; Robert A Pearce
Journal:  J Gen Physiol       Date:  2014-07       Impact factor: 4.086

10.  Correction for Inhibition Leads to an Allosteric Co-Agonist Model for Pentobarbital Modulation and Activation of α1β3γ2L GABAA Receptors.

Authors:  Alexis M Ziemba; Stuart A Forman
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

View more
  18 in total

1.  Analysis of GABAA Receptor Activation by Combinations of Agonists Acting at the Same or Distinct Binding Sites.

Authors:  Daniel J Shin; Allison L Germann; Douglas F Covey; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2018-10-18       Impact factor: 4.436

Review 2.  Applying the Monod-Wyman-Changeux Allosteric Activation Model to Pseudo-Steady-State Responses from GABAA Receptors.

Authors:  Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2018-10-17       Impact factor: 4.436

3.  Reduced Activation of the Synaptic-Type GABAA Receptor Following Prolonged Exposure to Low Concentrations of Agonists: Relationship between Tonic Activity and Desensitization.

Authors:  Spencer R Pierce; Allison L Germann; Alex S Evers; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2020-09-25       Impact factor: 4.436

4.  Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2019-12-16       Impact factor: 4.030

5.  High Constitutive Activity Accounts for the Combination of Enhanced Direct Activation and Reduced Potentiation in Mutated GABAA Receptors.

Authors:  Allison L Germann; Daniel J Shin; Christina R Kuhrau; Alexander D Johnson; Alex S Evers; Gustav Akk
Journal:  Mol Pharmacol       Date:  2018-02-08       Impact factor: 4.436

6.  Steady-State Activation and Modulation of the Concatemeric α1β2γ2L GABAA Receptor.

Authors:  Allison L Germann; Spencer R Pierce; Ariel B Burbridge; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2019-07-01       Impact factor: 4.436

7.  The Sulfated Steroids Pregnenolone Sulfate and Dehydroepiandrosterone Sulfate Inhibit the α1β3γ2L GABAA Receptor by Stabilizing a Novel Nonconducting State.

Authors:  Spencer R Pierce; Allison L Germann; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2021-12-01       Impact factor: 4.436

8.  (+)-Catharanthine potentiates the GABAA receptor by binding to a transmembrane site at the β(+)/α(-) interface near the TM2-TM3 loop.

Authors:  Hugo R Arias; Cecilia M Borghese; Allison L Germann; Spencer R Pierce; Alessandro Bonardi; Alessio Nocentini; Paola Gratteri; Thanvi M Thodati; Natalie J Lim; R Adron Harris; Gustav Akk
Journal:  Biochem Pharmacol       Date:  2022-03-15       Impact factor: 6.100

9.  Propofol Is an Allosteric Agonist with Multiple Binding Sites on Concatemeric Ternary GABAA Receptors.

Authors:  Daniel J Shin; Allison L Germann; Alexander D Johnson; Stuart A Forman; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2017-11-30       Impact factor: 4.436

Review 10.  Electrophysiology of ionotropic GABA receptors.

Authors:  Erwan Sallard; Diane Letourneur; Pascal Legendre
Journal:  Cell Mol Life Sci       Date:  2021-06-01       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.